

MEETING MINUTES

Consortium for Medical Marijuana Clinical Outcomes Research:

BOARD MEETING

May 30th, 2025, at 1:00 P.M. (EST)

Live and Remote Connection via Zoom

Attendees (in-person):

Max Orezzaoli
Dinender Singla
Christopher McCurdy
Troy Quast
Ken Dawson-Scully
Peter Holland
Almut Winterstein

Robert Cook
Jeevan Jyot
Yan Wang
Amie Goodin
Md Mahmudul Hasan
Catalina Lopez-Quintero
Allison Veliz

Attendees (virtual):

Charles Weatherford
Eric Holmes
Jacqueline Sagen

Welcome

Dr. Orezzaoli began the meeting by congratulating the Consortium team for another successful conference. Dr. Orezzaoli then welcomed the two new board members, Dr. Troy Quast from University of South Florida, and Dr. Ken Dawson-Scully, from Nova Southeastern University. Dr. Quast and Dr. Dawson-Scully introduced themselves to the board members and team.

CCORC 2025 Post Hoc

Dr. Goodin provided an overview of CCORC 2025, highlighting the fifth year of the conference. A total of 123 registrants included 36% students and attendance from all 11 Consortium member institutions and 10 U.S. states. The conference offered a total of 47 abstracts presented and showcased an increase in scientific sessions, the highest in the 5-year history of the conference. CME and CPE credits were offered for the three keynote lectures. A feedback survey will be sent out to all conference attendees and feedback received will be taken into consideration. The Medical Cannabis and Cannabinoids Journal will publish this year's conference abstracts.

Dr. Goodin requested feedback or suggestions from the board members regarding the conference. Dr. Orezzaoli suggested efforts for increasing attendance in subsequent years by inviting media outlets to attend and write articles on the conference, giving the Consortium a broader reach. Dr. Winterstein mentioned that she had spoken with the UF College of Pharmacy Communications Director who advised that media interest would likely be limited unless the conference could be linked to a specific hot topic that has media interest.

Dr. Orezzaoli also suggested possible collaboration with other conferences as recently initiated by a similar state-funded group in Colorado. Dr. Singla agreed and suggested exploring changing the conference venue, recognizing budgetary constraints. He will follow-up with Dr. Jyot. Dr. Winterstein welcomed the idea of moving the conference location but wanted the board to be mindful of travel issues for the two member institutions located in the panhandle should the conference be moved to South Florida. Other suggestions for expansion put forward by board

members included development of a CCORC information packet that could be placed on the website for easy reference and dissemination by the board members to Consortium member institution faculty, inviting representatives from Tallahassee, involvement of the VA and other organizations that represent veterans, and distribution of livestreams and achieved videos to interested parties. Dr. McCurdy suggested using the 5th year anniversary of the conference to write an op-ed for media outlets. Dr. Winterstein will follow-up on these suggestions and report back during upcoming board meetings.

Consortium Progress Updates and Upcoming Activities

Dr. Winterstein summarized the Consortium outputs as delineated in the Annual Report submitted to the Governor and legislative members in February 2025. Dr. Winterstein also reported presenting to the FL House Health Professions and Programs Subcommittee on February 4th, 2025, which was very well received.

Dr. Winterstein shared that the next steps for the Consortium include continuing projects in MEMORY and M³, expanding MEMORY linkages, publishing the results from the FDA collaboration on generating evidence syntheses on medical marijuana safety and effectiveness, continuing the development of the Researcher Spotlight Series, continuing the evidence in context series and newsletter, and start planning for the next grant cycle and 6th annual CCORC.

Public Comments

There were no public comments.

Closing Remarks

Dr. Winterstein extended a thank you to the Consortium team and board members.

Adjournment

Dr. Orezza adjourned the meeting at 2:14 p.m.